Search results
Mast cells–key effector cells in immune responses. M Metz, M Maurer. Trends in immunology 28 (5), 234-241. , 2007. 394. 2007. Mast cells in the promotion and limitation of chronic inflammation. M Metz, MA Grimbaldeston, S Nakae, AM Piliponsky, M Tsai, SJ Galli. Immunological reviews 217 (1), 304-328.
In this Review, we discuss the existing and emerging therapies that target mast cells, and we consider how these treatments can help us to understand mast cell functions in disease.
- Pavel Kolkhir, Pavel Kolkhir, Pavel Kolkhir, Daniel Elieh-Ali-Komi, Martin Metz, Martin Metz, Frank ...
- 2021
Aug 1, 2023 · Here, we review common targets, current treatments and emerging therapies for the treatment of five major type 2 chronic inflammatory diseases — atopic dermatitis, chronic prurigo, chronic ...
- Pavel Kolkhir
Martin METZ | Cited by 19,139 | of Charité Universitätsmedizin Berlin, Berlin (Charité) | Read 396 publications | Contact Martin METZ
In this review, we will (1) review the role of MCs in pathogenesis of CU, highlighting similarities with other MC disorders in disease mechanisms and response to treatment; (2) explore current therapeutic strategies, categorized by nonspecific immunosuppression, targeted inhibition of MC activation and mediators, and targeted modulation of MC ...
Oct 5, 2021 · Pavel Kolkhir, Martin Metz, Frank Siebenhaar & Marcus Maurer Allergology and Immunology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany
This review presents evidence that the skin mast cell, in particular the MC TC subtype, is the primary effector cell in urticaria. Mast cells are located in the upper dermis, the ideal situation for wheal formation and sensory nerve stimulation.
